Primary central nervous system tumors survival in children in ten Colombian cities: a VIGICANCER report

被引:2
作者
Ramirez, Oscar [1 ,2 ,3 ]
Piedrahita, Vivian [1 ,2 ,4 ]
Ardila, Jesus [1 ,2 ]
Pardo, Carlos [5 ,6 ]
Cabrera-Bernal, Edgar [5 ,6 ]
Lopera, John [7 ]
Suarez, Amaranto [7 ]
Portilla, Carlos Andres [1 ,2 ,8 ]
Narvaez, Carlos [1 ,2 ,8 ]
Rodriguez, Pamela [1 ,9 ]
Castro, Ximena [1 ,9 ]
Castro, Angel [10 ]
Estupinan-Perico, Diego Ivan [11 ]
Valencia, Diana [12 ]
Alvarez, Maria del Rosario [1 ,13 ]
Fox, Javier Enrique [14 ]
Bravo, Luis Eduardo [1 ,3 ]
Aristizabal, Paula [15 ,16 ,17 ,18 ]
机构
[1] Fdn Pediat Oncologos & Hematologos POHEMA, Un Invest, Cali, Colombia
[2] Un Oncol & Hematol Pediat, Clin Imbanaco Grp Quiron Salud, Cali, Colombia
[3] Univ Valle, Registro Poblac Canc Cali, Dept Patol, Cali, Colombia
[4] Univ Valle, Escuela Enfermeria, Cali, Colombia
[5] Hosp Misericordia HOMI Fdn Hosp Pediatr Misericord, Un Oncol & Hematol Pediat, Bogota, Colombia
[6] Grp Oncol & Hematol Pediat, Univ Nacl Colombia, Bogota, Colombia
[7] Un Oncol & Hematol Pediat, Inst Nacl Cancerol, Bogota, Colombia
[8] Univ Valle, Dept Pediat, Cali, Colombia
[9] Fdn Valle Lili, Un Oncol & Hematol Pediat, Cali, Colombia
[10] Univ Cartagena, Dept Pediat, Un Oncol & Hematol Pediat, Clin Blas Lezo, Cartagena, Colombia
[11] Un Oncol & Hematol Pediat, Clin Materno Infantil San Luis, Bucaramanga, Colombia
[12] Un Oncol & Hematol Pediat, Inst Med Alta Tecnol IMAT Oncomed, Monteria, Colombia
[13] Hosp Infantil Angeles, Un Oncol & Hematol Pediat, Pasto, Colombia
[14] Fdn San Vicente Paul, Un Oncol & Hematol Pediat, Medellin, Colombia
[15] Univ Calif San Diego, Dept Pediat, Div Pediat Hematol Oncol, San Diego, CA USA
[16] Rady Childrens Hosp San Diego, Pediat Hematol Oncol, San Diego, CA USA
[17] Univ Calif San Diego, Moores Canc Ctr, Populat Sci Dispar & Community Engagement, San Diego, CA USA
[18] Univ Calif San Diego, Altman Clin & Translat Res Inst, Disseminat & Implementat Sci Ctr, San Diego, CA USA
来源
FRONTIERS IN ONCOLOGY | 2024年 / 13卷
关键词
central nervous system neoplasms; pediatrics; treatment outcome; prognosis; epidemiology; Latin America; survival; children; CHILDHOOD-CANCER; INTERNATIONAL INCIDENCE; BRAIN-TUMORS; CLASSIFICATION; EPIDEMIOLOGY; ONCOLOGY; TRENDS; CARE;
D O I
10.3389/fonc.2023.1326788
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Primary central nervous system (CNS) tumors are the second most common cancer in children and adolescents, leading to premature death and disability. Population-based survival estimates aid decision-making in cancer control, however data on survival for primary CNS tumors in Latin America is lacking. We describe survival rates for children with primary CNS tumors treated in ten Colombian cities.Methods We analyzed data from children and adolescents newly diagnosed with cancer between 2012 and 2021, participating in the Childhood Cancer Clinical Outcomes Surveillance System (VIGICANCER) in ten cities in Colombia. VIGICANCER collects information on clinical outcomes from twenty-seven pediatric oncology units and conducts active follow-up every three months. VIGICANCER does not register craniopharyngiomas; we excluded intracranial germ cell tumors for this report. We used the Kaplan-Meier method to estimate the overall survival probability, stratified by sociodemographic variables, topography, WHO grading, receipt of radiation therapy, and type of surgical resection. We analyzed the prognostic capacity of variables using multivariate proportional Cox's regression, stratified by city and year of diagnosis.Results During the study period, VIGICANCER included 989 primary CNS tumors in 879 children and 110 adolescents. The cohort median age was 9 years; 53% of patients were males, and 8% were Afro-descendants. Most common tumors were supratentorial astrocytomas (47%), astrocytic tumors (35%), medulloblastomas (20%), ependymomas (11%), and mixed and unspecified gliomas (10%). Five-year overall survival of the entire cohort was 54% (95% CI, 51-58); for supratentorial gliomas, WHO grade I was 77%, II was 62%, III-IV was 27%, respectively, and for medulloblastoma was 61%. The adjusted hazard rate ratio for patients with WHO grade III and IV, for those with subtotal resection, for brainstem location, and for those not receiving radiation therapy was 7.4 (95% CI, 4.7-11.8), 6.4 (95% CI, 4.2-9.8), 2.8 (95% 2.1-3.8), 2.0 (95% CI, 1.3-2.8) and 2.3 (95% CI, 1.7-3.0), respectively.Conclusion We found that half of Colombia's children and adolescents with primary CNS tumors survive five years, compared to 70% to 80% in high-income countries. In addition to tumor biology and location, gross total resection was crucial for improved survival in this cohort. Systematic monitoring of survival and its determinants provides empirical data for guiding cancer control policies.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Neonatal Central Nervous System Tumors
    Shahab, Shubin
    Fangusaro, Jason
    CLINICS IN PERINATOLOGY, 2021, 48 (01) : 35 - 51
  • [42] The Epidemiology of Central Nervous System Tumors
    Francis, Stephen S.
    Ostrom, Quinn T.
    Cote, David J.
    Smith, Timothy R.
    Claus, Elizabeth
    Barnholtz-Sloan, Jill S.
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2022, 36 (01) : 23 - 42
  • [43] Clinical epidemiology for childhood primary central nervous system tumors
    Luc Bauchet
    Valérie Rigau
    Hélène Mathieu-Daudé
    Pascale Fabbro-Peray
    Gilles Palenzuela
    Dominique Figarella-Branger
    Jorge Moritz
    Stéphanie Puget
    Fabienne Bauchet
    Lorelei Pallusseau
    Hugues Duffau
    Philippe Coubes
    Brigitte Trétarre
    François Labrousse
    Patrick Dhellemmes
    Journal of Neuro-Oncology, 2009, 92
  • [44] Primary central nervous system primitive neuroectodermal tumors (CNS-PNETs) of the spinal cord in children: four cases from the German HIT database with a critical review of the literature
    Benesch, Martin
    Sperl, Daniela
    von Bueren, Andre O.
    Schmid, Irene
    von Hoff, Katja
    Warmuth-Metz, Monika
    Ferrari, Rudolf
    Lassay, Lisa
    Kortmann, Rolf-Dieter
    Pietsch, Torsten
    Rutkowski, Stefan
    JOURNAL OF NEURO-ONCOLOGY, 2011, 104 (01) : 279 - 286
  • [45] Outcome of children and adolescents with central nervous system tumors in phase I trials
    Carceller, Fernando
    Bautista, Francisco
    Jimenez, Irene
    Hladun-Alvaro, Raquel
    Giraud, Cecile
    Bergamaschi, Luca
    Dandapani, Madhumita
    Aerts, Isabelle
    Doz, Francois
    Frappaz, Didier
    Casanova, Michela
    Morland, Bruce
    Hargrave, Darren R.
    Vassal, Gilles
    Pearson, Andrew D. J.
    Geoerger, Birgit
    Moreno, Lucas
    Marshall, Lynley V.
    JOURNAL OF NEURO-ONCOLOGY, 2018, 137 (01) : 83 - 92
  • [46] Survival among patients with primary central nervous system lymphoma, 1973–2004
    Andrew D. Norden
    Jan Drappatz
    Patrick Y. Wen
    Elizabeth B. Claus
    Journal of Neuro-Oncology, 2011, 101 : 487 - 493
  • [47] Nutritional status and inflammatory markers as survival predictors in pediatric central nervous system tumors
    dos Santos, Isabelle Cristine Lopo
    Vargas Silva, Gabrielle da Silva
    Murad, Leonardo Borges
    Murad, Luana Dalbem
    CLINICAL NUTRITION ESPEN, 2023, 57 : 89 - 95
  • [48] INTERNATIONAL INCIDENCE OF CENTRAL-NERVOUS-SYSTEM TUMORS IN CHILDREN
    FILIPPINI, G
    ARTUSO, A
    ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES, 1992, 13 (05): : 395 - 400
  • [49] Increasing incidence of primary central nervous system lymphoma but no improvement in survival in Sweden 2000-2013
    Eloranta, Sandra
    Branvall, Elsa
    Celsing, Fredrik
    Papworth, Karin
    Ljungqvist, Maria
    Enblad, Gunilla
    Ekstrom-Smedby, Karin
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (01) : 61 - 68
  • [50] An epidemiology report for primary central nervous system tumors in adolescents and young adults: a nationwide population-based study in France, 2008-2013
    Ng, Sam
    Zouaoui, Sonia
    Bessaoud, Faiza
    Rigau, Valerie
    Roux, Alexandre
    Darlix, Amelie
    Bauchet, Fabienne
    Mathieu-Daude, Helene
    Tretarre, Brigitte
    Figarella-Branger, Dominique
    Pallud, Johan
    Frappaz, Didier
    Roujeau, Thomas
    Bauchet, Luc
    NEURO-ONCOLOGY, 2020, 22 (06) : 851 - 863